The Neuroprotective Effect of Byu d Mar 25 in LPS-Induced Alzheimer's Disease Mice Model

Figure 5

The expression levels of p-P38, P38, p-IκBα, caspase 1, COX2, and iNOS proteins in AD + NS, AD + donepezil, and AD + BM25 groups. Quantitative summaries of the protein levels relative to α-tubulin as an internal control, expressed as a percentage of α-tubulin optical density (o.d.) for the groups (n = 8/group). Statistical results (Kruskal–Wallis nonparametric test with Dunn’s multiple post-hoc comparison) were shown in the bar graphs, with “^∗∗” indicating significant intergroup difference. Data are expressed as the mean ± standard error of the mean (SEM) (n = 8/group). (a) Expression levels of p-P38 in AD + NS, AD + donepezil, and AD + BM25 groups; (b) expression levels of P38 in AD + NS, AD + donepezil, and AD + BM25 groups; (c) expression levels of p-IκBα in AD + NS, AD + donepezil, and AD + BM25 groups; (d) expression levels of Caspase1 in AD + NS, AD + donepezil, and AD + BM25 groups; (e) expression levels of COX2 in AD + NS, AD + donepezil, and AD + BM25 groups; (f) expression levels of iNOS in AD + NS, AD + donepezil, and AD + BM25 groups. BM25: Byu d Mar 25; AD: Alzheimer’s disease; NS: normal saline.

(a)

(b)